Using RNA to interfere with a gene’s expression of disease-causing proteins is a validated therapeutic approach, but so far, the products in this drug class only address liver proteins. Reducing ...

Honeybees are vital to global food security, yet colony collapse threatens ecosystems and agriculture worldwide.   Discover how Genolution, in pa | Ebooks ...

Arrowhead’s stock rose 6% on market open after the announcement though continued to rise throughout the day.

Arrowhead Pharmaceuticals recently reported interim Phase 1/2a data showing its RNAi obesity candidates ARO-INHBE and ARO-ALK7 reduced visceral and liver fat and enhanced weight loss versus ...

Please provide your email address to receive an email when new articles are posted on . RNA therapeutics lowered all-cause mortality, increased 6-minute walk distance and improved quality of life. RNA ...

SenseUP’s platform tech could overcome the cost and stability hurdles holding back RNAi-based crop protection, claims the ...

Arrowhead Pharmaceuticals (NASDAQ:ARWR) used its presentation at the JPMorgan Healthcare Conference to highlight a newly launched RNA interference (RNAi) therapy, a broad clinical-stage pipeline, and ...

It was not until 2018 that the US FDA approved the first therapy developed using the technique. Since then, there’s been a steady, but slow, number of RNAi treatments coming into the market. The ROBO ...

BOSTON--(BUSINESS WIRE)--Atalanta Therapeutics, a biotechnology company pioneering RNA interference (RNAi) for the treatment of neurological diseases, today announced the completion of a $97 million ...

Patients receiving concomitant PCSK9 inhibitor therapy experienced greater LDL cholesterol reductions, exceeding 50% during ...

RNA interference (RNAi) is a fundamental cellular mechanism that regulates gene expression by inducing sequence-specific mRNA degradation. Researchers could utilize the RNAi as a powerful tool to ...